Camurus AB

Latest Results (06.10.2025):

Camurus AB reported a strong performance in the second quarter of 2025, showcasing significant growth in revenues and profitability. The company's total revenues increased by 52% to SEK 676 million, driven by robust sales of Buvidal® and a doubling of Brixadi® royalties. Profit before tax surged by 195%, reflecting the company's efficient operations and expanding market presence.

Revenue Growth

Total revenues for Camurus AB rose by 52% to SEK 676 million in Q2 2025, compared to SEK 445 million in the same period last year. This growth was primarily fueled by a 17% increase in Buvidal® sales and a 100% rise in Brixadi® royalties.

Profitability Enhancement

Profit before tax saw a substantial increase of 195%, reaching SEK 307 million in the second quarter of 2025, up from SEK 104 million in Q2 2024. This improvement underscores Camurus AB's strong financial health and effective cost management.

Strong Product Performance

Buvidal® sales grew by 17% to SEK 470 million, while Brixadi® royalties doubled to SEK 89 million. These results highlight the company's successful market penetration and the robust demand for its pharmaceutical products.

Strategic Collaborations and Approvals

Camurus AB entered into a collaboration and license agreement with Eli Lilly and Company for long-acting FluidCrystal® incretins, generating an initial license revenue of USD 12 million. Additionally, the European Commission granted marketing authorization for Oczyesa® for the treatment of acromegaly, further strengthening the company's product portfolio.

Financial Stability

The company's cash position at the end of Q2 2025 stood at SEK 3.3 billion, up from SEK 2.6 billion in the previous quarter. Camurus AB also maintained its financial outlook for 2025, demonstrating continued confidence in its growth trajectory.